CAMBRIDGE, Mass., May 17, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management plans to participate in fireside chats during the following May investor conferences:
- Barclays Virtual Gene Editing & Therapy Summit 2023 on Wednesday, May 24, 2023 at 11:05 a.m. ET;
- Stifel 2023 Tailoring Genes: Virtual Genetic Medicines on Tuesday, May 30, 2023 at 10:20 a.m. ET.
Live webcasts will be available in the investor section of the company's website at www.beamtx.com, and will be archived for 60 days following the presentation.
About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.
THRUST Strategic Communications